The world’s second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm. Emodepside originates from the Japanese pharmaceutical company Astellas
The Company has spent months in resources to locate quality organic CBD oil, toxin and heavy metal free, for the US market. We are pleased that we have
Cancer therapy often results in the patient becoming very sick due to toxicity and off-target effects of certain drugs used to treat patients. ADCs take advantage of the
Consistent with prior guidance, earlier this year, Mast Therapeutics submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA), together with the protocol
INNs facilitate the identification of active pharmaceutical ingredients, and each INN is a globally recognized unique name. As a novel, orally available, selective tyrosine kinase inhibitor of the
HealthPatch MD can be used with Medidata’s industry-leading technology platform (Medidata Clinical Cloud) and its mobile app for patient-reported outcomes (Medidata Patient Cloud) to further remote patient monitoring,
Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies. Can-Fite reports today that it received positive pre-clinical data
Endo will collaborate with Trimel on all regulatory and clinical development activities regarding Natesto, which was approved by the U.S. Food and Drug Administration (FDA) in May of
NHI drug price listing: November 25, 2014) in Japan for the recently approved indications: the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation
Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates. Additionally, the parties will collaborate to discover and validate new targets that play
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.